. 2016 Sep 7;6:32714. doi: 10.1038/srep32714

Table 1. Baseline characteristics of patients in the trials included in the meta-analysis.

Study	Year	Intervention	No. of patients	Age(mean ± SD, y)	Duration of T2DM (mean ± SD, y)	Hb1Ac (mean ± SD, %)	Weight(mean ± SD, kg)	Jadad score
Nauck M¹⁹	2009	0.6 mg liraglutide	242	56±11	7±5	8.4±0.9	NR	4
		1.2 mgliraglutide	242	57±9	7±5	8.3±1.0	NR
		1.8 mg liraglutide	242	57±9	8±5	8.4±1.0	NR
		4 mg glimepiride	123	57±9	8±5	8.4±1.0	NR
		Placebo	242	56±9	8±6	8.4±1.1	NR
Russell-Jones D²⁰	2009	1.8 mg liraglutide	232	57.6±9.5	9.2±5.8	8.3±0.9	85.5±19.4	4
		Placebo	115	57.5±9.6	9.4±6.2	8.3±0.9	85.7±16.7
		24 IU insulin glargine	234	57.5±10.5	9.7±6.4	8.2±0.9	85±17.9
Dungan KM⁴¹	2014	1.8 mg liraglutide	300	56.8±9.9	7.3±5.4	8.1±0.8	94.4±19	4
Dungan KM⁴¹	2014	1.5 mg dulaglutide	299	56.5±9.3	7.1±5.4	8.1±0.8	93.8±18.2	4
Ma ZJ⁴²	2015	1.8 mg liraglutide	31	51.3±12.5	NR	10.1±1.4	77.3±2.1	3
Ma ZJ⁴²	2015	NPH	32	52.5±11.7	NR	9.8±1.8	76.7±2.3	3
Davies M⁴³	2011	1.2 mg liraglutide	164	NR	NR	8.4	93.7	3
		1.8 mg liraglutide	171	NR	NR	8.4	94.6
		100 mg sitagliptin	170	NR	NR	8.5	93.1
Brady EM⁴⁴	2014	1.2 mg liraglutide	47	51.5±11.1	NR	7.6±1.1	86.1±16.9	4
Brady EM⁴⁴	2014	4 mg glimepiride	52	52.2±10.7	NR	7.8±1.0	79±11.2	4
Yang W⁴⁵	2011	0.6 mg liraglutide	231	53.5±9.5	7.4±5.4	8.5±1.1	68.6±11.6	3
		1.2 mg liraglutide	233	53.5±9.6	7.5±5.3	8.6±1.1	67.4±11.3
		1.8 mg liraglutide	234	52.7±9.1	7.2±5.2	8.6±1.1	68.2±11.9
		4 mg glimepiride	231	53.6±9.7	7.8±6.1	8.5±1.1	68.2±11.9
Charbonnel B⁴⁶	2013	1.2 mgliraglutide	327	67.6±10.8	8.2±6.2	8.1±0.9	92.1±20.4	3
Charbonnel B⁴⁶	2013	100 mg sitagliptin	326	56.9±10	7.6±4.8	8.2±1.1	91±20.5	3
Pratley R⁴⁰	2011	1.2 mgliraglutide	135	55.9±9.6	6.0±4.5	8.4±0.8	NR	3
		1.8 mg liraglutide	150	55.0±9.1	6.4±5.4	8.4±0.7	NR
		100 mg sitagliptin	151	55.0±9.0	6.3±5.4	8.5±0.7	NR

Abbreviation: NR, not reported; SD, standard deviation.